Top Small Cap Stocks To Own For 2018

Related KERX Mid-Day Market Update: Conn's Drops Following Weak Q1 Results; Achaogen Shares Surge Mid-Morning Market Update: Markets Open Lower; Joy Global Profit Tops Expectations Keryx up 15% on disclosure of Klarman stake (Seeking Alpha)
Related FOLD Amicus Therapeutics Gets European Commission Approval For Galafold in Patients With Fabry Disease Today's Top 10 Pre-Market Gainers Biotech Daily Digest: The Biotech Rally Continues; Another Small Cap Gets Bought Out; Icahn Targets Allergan (Seeking Alpha)

Toward the end of trading Thursday, the Dow traded up 0.18 percent to 17,821.51 while the NASDAQ climbed 0.21 percent to 4,962.80. The S&P also rose, gaining 0.16 percent to 2,102.65.

Leading and Lagging Sectors

Thursday afternoon, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Keryx Biopharmaceuticals (NASDAQ: KERX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD).

Top Small Cap Stocks To Own For 2018: Tencent Holdings Ltd (700)

Advisors’ Opinion:

  • [By Belinda Cao]

    Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.

Top Small Cap Stocks To Own For 2018: Iteris, Inc.(ITI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Top Small Cap Stocks To Own For 2018: SK TELECOM ADR EACH REP 1/9 KRW500(CIT)

Advisors’ Opinion:

  • [By Lisa Abramowicz]

    There was this maturity wall that people were terrified of, said Neil Wessan, the group head of New York-based CIT Group Inc. (CIT)s capital markets unit. Thats been spread out over a much broader period of time.

  • [By Ben Levisohn]

    We will admit that these latter assumptions are somewhat arbitrary, but nevertheless we cannot help escape the view that in 2017 everything will likely be at least a little adverse to prior expectations. On average our estimate reductions are 8%, and range from 3% at CIT Group (CIT) to 13% at Goldman Sachs. With that, we are lowering our PT of Bank of America,Citigroup andGoldman Sachs from $20, $70 and $243 to $18, $63 and $214, respectively…

Leave a Reply

Your email address will not be published. Required fields are marked *